ClinicalTrials.gg
RecruitingNCT06915480Updated Mar 18, 2026

Reducing Missed Appointments

A Phase 3 interventional study of Reminder message and patient navigation in Neurodevelopmental Disorders, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. Recruiting at 1 site in United States. Open to participants aged 1 Month to 24 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Phase 3, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,000
Allocation
Randomized
Ages
1 Month to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.

Planned enrollment
Largest of 60
5,000 · median 100
Started
2025
with 7 others
Phase 3
11 of 100
3 open now
Primary completion
2026-12
later than 11 of 52 live
Registered
87th of 100
by date

Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one has the largest planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 11 of the 52 other live ones, and was the 87th registered.

Neurodevelopmental Disorders

355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: 1 Month to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Neurodevelopmental Disorders with a site in United States, or all of them as a file.
02

Study summary

There are four goals of this project: (1) To examine the impact of different appointment reminder messages on appointment attendance; (2) to determine the added benefit of a patient navigator reaching out in advance of appointments to families at elevated risk of missing their appointment, and determine the most common barriers families face in appointment attendance; (3) to evaluate which patients are at highest risk of missing their appointment, and to determine the effectiveness of the intervention trial across different patient risk levels; and (4) to examine if the missing appointment interventions increase the socioeconomic diversity patients.

Read the detailed description

Aim 1: To test messaging strategies aimed at reducing missed appointments, via a randomized trial, across two different Kennedy Krieger outpatient clinics. Using the reminder system timeline and contact strategy already in effect in these two centers, the investigators will trial alternative language in the reminders (i.e., enhanced message #1 and enhanced message #2) against the current standard of care language. Hypothesis 1: Enhanced messaging will be superior to the standard of care in terms of reducing missed appointments. The investigators do not make a priori hypotheses regarding which enhanced messaging strategy will be optimal, given the exploratory nature.

Aim 2: To determine the added benefit of receiving patient navigation services for families at elevated risk of missing their appointment, and to understand the barriers to child neurodevelopmental evaluation appointments for the purposes of informing future interventions. Throughout the intervention trial, the patient navigator will continuously gather qualitative information on the barriers to appointment attendance faced by families identified to be at elevated risk of missing their evaluation appointment. Understanding these barriers will be critical to the development of future intervention efforts. Hypothesis 2a: Patient navigation services will be superior to enhanced or standard messaging alone in reducing missed appointments. Hypothesis 2b: Most families contacted by the patient navigator will face more than one barrier to attendance, and most barriers will fall into thematic categories that can be used to develop targeted interventions.

Aim 3: To examine the factors related to missed appointments. While the study team has previously identified families that are high-risk for missing their child's appointment, how those family and child-related factors replicate in a novel clinic is unknown. Hypothesis 3: The missing appointment factors will generally reproduce in an independent clinic, Center for Autism (n\~3600 yearly diagnostic evaluation appointments), and generally reproduce in the updated data within Center for Neuropsychological and Psychological Assessment (n\~6,200 yearly diagnostic evaluation appointments). This will allow the investigators to determine if the intervention is effective particularly for families at elevated risk of missing their appointment (Aim 4).

Aim 4: To examine if the missing appointment interventions increase the socioeconomic diversity of Kennedy Krieger patients. Previous research shows families from less advantaged socioeconomic backgrounds are more likely to miss their appointments. The goal of the intervention is to increase equity among Kennedy Krieger patients, rather than sacrificing equity at the expense of higher show rates (e.g., using punitive procedures). Hypothesis 4: More families at elevated risk of missing their appointments will attend their appointments when receiving the enhanced messages compared to standard messages, and further supported via patient navigation.

03

Conditions studied

  • Neurodevelopmental Disorders
04

Who can participate

Ages eligible
1 Month to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who are scheduled to be seen within the center for autism or the center for neuropsychological and psychological assessment for evaluation appointments will be automatically enrolled in the reminder message portion of the intervention trial.
  • Patients who are at elevated risk within the center for neuropsychological and psychological assessment are automatically enrolled in the patient navigator portion of the intervention trial.

Exclusion criteria

Exclusion criteria:

  • None for the messaging portion of the study
  • For patient navigation, patients >18 years of age will be excluded.
05

Study design

Phase
Phase 3
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Care provider)
Enrollment
5,000 participants (estimated)

Study arms

  • Active comparator
    Standard message, no navigator

    This arm represents the standard operating procedures. It includes basic appointment information and no personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

  • Experimental
    Standard message with navigator

    This arm represents the standard pre-appointment reminder message. This arm will include personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

  • Experimental
    Enhanced message #1, no navigator

    This arm represents a novel pre-appointment reminder message based on existing scientific literature. This arm will not include personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

  • Experimental
    Enhanced message #1 with navigator

    This arm represents a novel pre-appointment reminder message based on existing scientific literature. This arm will include personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

  • Experimental
    Enhanced message #2, no navigator

    This arm represents a second novel pre-appointment reminder message based on existing scientific literature. This arm will not include personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

  • Experimental
    Enhanced message #2 with navigator

    This arm represents a second novel pre-appointment reminder message based on existing scientific literature. This arm will include personal assistance with appointment navigation.

    Behavioral: Reminder message and patient navigation

Interventions

  • BehavioralReminder message and patient navigation

    This study will evaluate the combination of pre-appointment messages and patient navigation services.

06

What researchers measure

Primary outcomes

  1. Patient appointment no-show

    Proportion of appointments that are neither kept nor cancelled

    Time frame: 6 months

Secondary outcomes

  1. Patient appointment cancel

    Proportion of appointments that are cancelled (\>48 hours of appointment date)

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Kennedy Krieger Institute
    Baltimore, Maryland 21211, United States
    Recruiting
    • Luke Kalb · Contact443-923-9439
    • Luther Kalb, PhD · Principal investigator
08

References and documents

Publications

  • Gornik AE, Northrup RA, Kalb LG, Jacobson LA, Lieb RW, Peterson RK, Wexler D, Ludwig NN, Ng R, Pritchard AE. To confirm your appointment, please press one: Examining demographic and health system interface factors that predict missed appointments in a pediatric outpatient neuropsychology clinic. Clin Neuropsychol. 2024 Feb;38(2):279-301. doi: 10.1080/13854046.2023.2219421. Epub 2023 Jun 8. PubMed 37291078 ↗
  • Kalb LG, Freedman B, Foster C, Menon D, Landa R, Kishfy L, Law P. Determinants of appointment absenteeism at an outpatient pediatric autism clinic. J Dev Behav Pediatr. 2012 Nov-Dec;33(9):685-97. doi: 10.1097/DBP.0b013e31826c66ef. PubMed 23095496 ↗
  • Berliner Senderey A, Kornitzer T, Lawrence G, Zysman H, Hallak Y, Ariely D, Balicer R. It's how you say it: Systematic A/B testing of digital messaging cut hospital no-show rates. PLoS One. 2020 Jun 23;15(6):e0234817. doi: 10.1371/journal.pone.0234817. eCollection 2020. PubMed 32574181 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 8, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 1, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06915480
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Dec 29, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

luther G kalb, PhD
Contact
kalb@kennedykrieger.org
4439239439
luther G kalb, PhD
principal investigator · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion